T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update

T2 Biosystems, Inc. (NASDAQ:TTOO) saw a large decline in short interest in December. As of December 15th, there was short interest totalling 624,900 shares, a decline of 28.6% from the November 30th total of 875,200 shares. Based on an average daily volume of 782,300 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the company’s stock are sold short.

T2 Biosystems Price Performance

NASDAQ TTOO remained flat at $0.43 during mid-day trading on Monday. 1,393,547 shares of the company were exchanged, compared to its average volume of 408,612. T2 Biosystems has a 52 week low of $0.31 and a 52 week high of $6.95. The business’s 50-day moving average price is $0.62 and its two-hundred day moving average price is $2.61.

Institutional Trading of T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC bought a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned about 9.49% of T2 Biosystems as of its most recent filing with the SEC. 23.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of T2 Biosystems in a research note on Saturday. They set a “sell” rating for the company.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.